Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis  by McKerrell, Thomas et al.
ReportLeukemia-Associated Somatic Mutations Drive
Distinct Patterns of Age-RelatedClonal HemopoiesisGraphical AbstractHighlightsd Clonal hemopoiesis is an almost inevitable consequence of
aging in humans
d Spliceosome gene mutations drove clonal hemopoiesis only
in persons agedR70 years
d NPM1 mutations behave as gatekeepers for leukemogenesisMcKerrell et al., 2015, Cell Reports 10, 1239–1245
March 3, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.02.005Authors
Thomas McKerrell, Naomi Park, ...,
Ignacio Varela, George S. Vassiliou
Correspondence
gsv20@sanger.ac.uk
In Brief
McKerrell et al. employ ultra-deep
sequencing to show that age-related
clonal hemopoiesis is much more
common than previously realized. They
find that clonal hemopoiesis, driven by
mutations in spliceosome genes SF3B1
and SRSF2, was noted exclusively in
individuals aged 70 years or older and
that NPM1 mutations are not seen in
association with this phenomenon,
endorsing their close association with
leukemogenesis.
Cell Reports
ReportLeukemia-Associated Somatic Mutations Drive
Distinct Patterns of Age-Related
Clonal Hemopoiesis
Thomas McKerrell,1,13 Naomi Park,2,13 Thaidy Moreno,3 Carolyn S. Grove,1 Hannes Ponstingl,1 Jonathan Stephens,4,5
Understanding Society Scientific Group,6 Charles Crawley,7 Jenny Craig,7 Mike A. Scott,7 Clare Hodkinson,4,8
Joanna Baxter,4,8 Roland Rad,9,10 Duncan R. Forsyth,11 Michael A. Quail,2 Eleftheria Zeggini,12 Willem Ouwehand,4,5,12
Ignacio Varela,3 and George S. Vassiliou1,4,7,*
1Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK
2Sequencing Research Group, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK
3Instituto de Biomedicina y Biotecnologı´a de Cantabria (CSIC-UC-Sodercan), Departamento de Biologı´a Molecular, Universidad de
Cantabria, 39011 Santander, Spain
4Department of Haematology, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0XY, UK
5NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0PT, UK
6Institute for Social and Economic Research, University of Essex, Colchester CO4 3SQ, UK
7Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, UK
8Cambridge Blood and Stem Cell Biobank, Department of Haematology, University of Cambridge, Cambridge CB2 0XY, UK
9Department of Medicine II, Klinikum Rechts der Isar, Technische Universita¨t Mu¨nchen, 81675 Mu¨nchen, Germany
10German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
11Department of Medicine for the Elderly, Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, UK
12Human Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK
13Co-first author
*Correspondence: gsv20@sanger.ac.uk
http://dx.doi.org/10.1016/j.celrep.2015.02.005
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARY
Clonal hemopoiesis driven by leukemia-associated
genemutations can occurwithout evidence of a blood
disorder. To investigate this phenomenon, we interro-
gated 15 mutation hot spots in blood DNA from 4,219
individuals using ultra-deep sequencing. Using only
the hot spots studied, we identified clonal hemopoie-
sis in 0.8% of individuals under 60, rising to 19.5% of
thoseR90 years, thus predicting that clonal hemopoi-
esis is much more prevalent than previously realized.
DNMT3A-R882 mutations were most common and,
although their prevalence increased with age, were
found in individuals as young as 25 years. By contrast,
mutations affecting spliceosome genes SF3B1 and
SRSF2, closely associated with the myelodysplastic
syndromes, were identified only in those aged >70
years, with several individuals harboring more than
one such mutation. This indicates that spliceosome
genemutationsdriveclonal expansionunderselection
pressures particular to the aging hemopoietic system
and explains the high incidence of clonal disorders
associated with thesemutations in advanced old age.
INTRODUCTION
Cancers develop through the combined action of multiple muta-
tions that are acquired over time (Nowell, 1976). This paradigm isCewell established in hematological malignancies, whose clonal
history can be traced back for several years or even decades
(Ford et al., 1998; Kyle et al., 2002). It is also clear from studies
of paired diagnostic-relapsed leukemia samples that recurrent
disease can harbor some, but not always all, mutations present
at diagnosis, providing evidence for the presence of a clone of
ancestral pre-leukemic stem cells that escape therapy and
give rise to relapse through the acquisition of new mutations
(Ding et al., 2012; Kro¨nke et al., 2013). Studies of such phenom-
ena have defined a hierarchical structure among particular leu-
kemia mutations, with some, such as those affecting the gene
DNMT3A, displaying the characteristics of leukemia-initiating le-
sions and driving the expansion of hemopoietic cell clones prior
to the onset of leukemia (Ding et al., 2012; Shlush et al., 2014).
These observations suggest that individuals without overt fea-
tures of a hematological disorder may harbor hemopoietic cell
clones carrying leukemia-associated mutations. In fact, such
mutations, ranging from large chromosomal changes (Jacobs
et al., 2012; Laurie et al., 2012) to nucleotide substitutions (Bus-
que et al., 2012), have been found to drive clonal hemopoiesis in
some individuals. Recent reanalyses of large exome-sequencing
data sets of blood DNA showed that clonal hemopoiesis is more
common than previously realized and increases with age to
affect up to 11% of those over 80 and 18.4% of those over
90 years (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al.,
2014). The presence of such clones was associated with an
increased risk of developing hematological or other cancers
and a higher all-cause mortality, probably due to an increased
risk of cardiovascular disease (Genovese et al., 2014; Jaiswal
et al., 2014).ll Reports 10, 1239–1245, March 3, 2015 ª2015 The Authors 1239
Table 1. Mutation Hot Spots Interrogated in This Study
Gene Target Codon
DNMT3A R882
JAK2 V617
NPM1 L287
SRSF2 P95
SF3B1 K666
SF3B1 K700
IDH1 R132
IDH2 R140
IDH2 R172
KRAS G12
NRAS G12
NRAS Q61
KIT D816
FLT3 D835
FLT3 N676
Also see Table S1 for detailed information about numbers of samples
screened for each mutation.The important findings of these studies were based on anal-
ysis of exome-sequencing data sets that were generated for
the study of constitutional genomes, thus trading genome-
wide coverage for reduced sensitivity for detecting small subclo-
nal events. We used the different approach of targeted re-
sequencing of selected leukemia-associated mutation hot spots
in blood DNA from more than 4,000 individuals unselected for
blood disorders. In addition to increasing the sensitivity for de-
tecting subclonal mutations, this approach enabled us to pro-
spectively select and study a large number of elderly individuals.
Our results show that clonal hemopoiesis is significantly more
common than anticipated, give new insights into the distinct
age-distribution and biological behavior of clonal hemopoiesis
driven by different mutations, and help explain the increased
incidence of myelodysplastic syndromes (MDSs) with advancing
age.
RESULTS
To investigate the incidence, target genes, and age distribution
of age-related clonal hemopoiesis (ARCH), we performed tar-
geted re-sequencing for hot spotmutations at 15 gene loci recur-
rently mutated in myeloid malignancies (Table 1) using blood
DNA from 3,067 blood donors aged 17–70 (Wellcome Trust
Case Control Consortium [WTCCC]) and 1,152 unselected
individuals aged 60–98 years (United Kingdom Household
Longitudinal Study [UKHLS]; see Figure S1 for detailed age dis-
tributions). To do this, we developed and validated a robust
methodology, employing barcoded multiplex PCR of mutational
hot spots followed by next-generation sequencing (MiSeq) and
bioinformatic analysis, to extract read counts and allelic fractions
for reference and non-reference nucleotides. This reliably de-
tected mutation-associated circulating blood cell clones with a
variant allele fraction (VAF) R 0.008 (0.8%; see Supplemental
Experimental Procedures and Figure S2).1240 Cell Reports 10, 1239–1245, March 3, 2015 ª2015 The AuthorsWe obtained adequate coverage (R1,000 reads at all studied
hot spots) from 4,067 blood DNA samples and identified muta-
tion-bearing clones in 105 of these. Of note, not all hot spots
were studied in all samples and the derived incidence of muta-
tions in our population as a whole was 3.24% (Table S1). How-
ever, the incidence rose significantly with age from 0.2% in the
17–29 to 19.5% in the 90–98 years age group (Figure 1A). We
found one or more samples with mutations at 9 of the 15 hot
spot codons studied, with VAFs varying widely within and be-
tween mutation groups (Table 2).
The most-common mutations were those affecting DNMT3A
R882, whose incidence rose with age from 0.2% (1/489) in the
17–25 to a peak of 3.1% (11/355) in the 80–89 age group. A
similar pattern was observed with JAK2 V617F mutations (Fig-
ure 1A). By contrast, spliceosome gene mutations at SRSF2
P95, SF3B1 K666, and SF3B1 K700 were exclusively observed
in people aged over 70 years, rising sharply from 1.8% in those
aged 70–79 to 8.3% in the 90–98 years age group. Among all
samples, we identified only six individuals with more than one
mutation; significantly, five of them had two independent spli-
ceosome gene mutations of different VAFs (Figure 1B). Unfortu-
nately, in each of three cases with two mutations at the same or
nearby positions, neighboring SNPs were not informative and
the variants could not be phased (see Supplemental Experi-
mental Procedures).Occasional mutations in the genes IDH1,
IDH2, NRAS, and KRAS were also seen. Except for three sam-
ples with IDH1/2 mutations, hemoglobin concentrations did not
differ significantly between individuals with and without hot
spot mutations (Figure S3A). For samples with full blood count
results available, JAK2 V617Fmutant cases had a higher platelet
count (albeit within the normal range) than ‘‘no mutation cases,’’
whereas other results did not differ (Figure S3B). No hot spot mu-
tations were found in the few cord blood (n = 18) and post-trans-
plantation (n = 32) samples studied.
Finally, despite using a very sensitive method and a mutation-
calling script written specifically for this purpose, no samples
with NPM1 mutations of VAF R 0.008 were identified. In fact,
variant reads reporting a canonical NPM1mutation (mutation A;
TCTG duplication) were detected in only 1 of 4,067 samples at a
VAF of 0.0012 (4/3,466 reads).
DISCUSSION
Hematological malignancies develop through the serial acquisi-
tion of somatic mutations in a process that can take many years
or even decades (Ford et al., 1998; Kyle et al., 2002). Also, it is
clear that the presence of hemopoietic cells carrying leukemia-
associatedmutations is only followed by the onset of hematolog-
ical malignancies in a minority of cases (Busque et al., 2012;
Genovese et al., 2014; Jacobs et al., 2012; Jaiswal et al., 2014;
Laurie et al., 2012; Xie et al., 2014). In order to understand the
incidence and clonal dynamics of pre-leukemic clonal hemopoi-
esis, we interrogated 15 leukemia-associatedmutation hot spots
using a highly sensitive methodology able to detect small clones
with mutations.
We show that clonal hemopoiesis is rare in the young but be-
comes common with advancing age. In particular, we observed
that ARCH driven by the mutations studied here doubled in
Figure 1. Prevalence and Age Distribution
of Hot Spot Mutations Driving Clonal Hemo-
poiesis
(A) Prevalence of mutations driving clonal hemo-
poiesis by age.
(B) Samples with more than one mutation, variant
allele fraction (VAF) of each mutation present, and
age of participant.
Also see Figure S1 for age distribution of all
participants.frequency in successive decades after the age of 50, rising from
1.5% in those aged 50–59 to 19.5% in those aged 90–98 (Fig-
ure 1). Of note, 61 of 112 clones identified had a VAF % 3%
(Table 2), and it is likely that most of these would not have
been detected by conventional exome sequencing, which gives
lower than 10-fold average coverage compared to the current
study (see Table S2 for comparison to such studies), with
some recurrently mutated regions giving particularly low cover-
age (Genovese et al., 2014). Notably, our study did not search
for non-hot-spot mutations associated with ARCH such as those
affecting genes TET2 and ASXL1 or DNMT3A codons other than
R882 (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).
Assuming that the incidence of small clones is similar for such
mutations as for the hot spot mutations we studied here, the
mean projected true incidence of ARCH driven by leukemia-
associated mutations in those older than 90 years is greater
than 70% (Figure S4). This makes clonal hemopoiesis an almost
inevitable consequence of advanced aging.
Another significant finding of our study is the disparate age
distribution of ARCH associated with different mutation types.
In particular, we found that, although DNMT3A R882 and JAK2
V617F mutations become more common with age, they were
also found in younger individuals. This is in keeping with the
increasing cumulative likelihood of their stochastic acquisition
with the passage of time. In contrast, spliceosome gene muta-
tions were found exclusively in those aged 70 years or older,
replicating the sharp rise beyond this age in the incidence of
MDSs driven by these mutations and the fact that, among unse-
lected MDS patients, those with spliceosome mutations are
significantly older than those without (Haferlach et al., 2014;
Lin et al., 2014; Papaemmanuil et al., 2013; Wu et al., 2012).Cell Reports 10, 1239–124Exome-sequencing studies describe a
much-lower rate of spliceosome muta-
tions (Genovese et al., 2014; Jaiswal
et al., 2014; Xie et al., 2014), but this is
again likely to reflect their lower sensitivity
for detecting small clones, which was a
particular limitation at spliceosomemuta-
tion hot spots as these were captured/
sequenced at lower-than-average depths
(Table S2). In our study, 19/33 SF3B1- or
SRSF2-associated clones had a VAF %
5%, with 13 of these at VAFs% 3% (Ta-
ble 2), the majority of which would not
have been detected by low-coverage
sequencing. The identification of ARCHdriven by spliceosome gene mutations is in keeping with the
fact that these are founding mutations in the clonal evolution of
MDS and related hematological malignancies (Cazzola et al.,
2013; Haferlach et al., 2014; Papaemmanuil et al., 2013).
We propose that the exclusive identification of spliceosome
gene mutations in those aged R70 years can be explained by
differences in the prevailing pressures on clonal selection at
different ages, which can in turn explain how different gene mu-
tations can generate detectable clonal expansions at different
ages (Figure 2). The alternatives are that spliceosome mutations
are associated with slower rates of clonal expansion or that they
are detected later because they contribute less to circulating leu-
kocytes. Both of these scenarios are less plausible, given the
complete absence of such mutations even at low VAFs in
younger age groups. For any somaticmutation imparting a clonal
advantage to a stem/progenitor cell and leading to the genera-
tion of a steadily expanding clone, one would expect such a
clone to be detectable at a smaller size at earlier and a larger
size at later time points, as is the case for DNMT3A R882 and
JAK2 V617 mutations. Instead, clones (of any size) driven by
mutant SRSF2 and SF3B1 were observed exclusively in individ-
uals aged 70 years or older, suggesting that these only begin to
expand later in life. Furthermore, considerable support for the
presence of a different selection milieu comes from the observa-
tion that five of six patients with multiple mutations harbored two
independent spliceosome gene mutations, indicative of conver-
gent evolution, i.e., evolution to overcome a shared selective
pressure or to exploit a shared environment (Greaves andMaley,
2012; Rossi et al., 2008).
It is tempting to consider the nature of age-related changes in
normal hemopoiesis that make it permissive to the outgrowth of5, March 3, 2015 ª2015 The Authors 1241
Table 2. Amino Acid Consequences and VAFs of the 112 Clonal Mutations Identified in This Study
Mutation
Hot Spot Codon VAF (%) Age
Mutation
Hot Spot Codon VAF (%) Age
Mutation
Hot Spot Codon VAF (%) Age
DNMT3A R882 p.R882H 4.14 25 p.R882H 32.02 81 IDH1 R132 p.R132H 42.13 84
p.R882C 2.33 35 p.R882H 1.14 81 p.R132C 0.92 92
p.R882H 3.80 42 p.R882H 3.06 81 IDH2 R140 p.R140Q 6.67 76
p.R882H 4.00 42 p.R882H 2.17 81 SRSF2 P95 p.P95R 4.46 70
p.R882H 1.25 43 p.R882H 1.13 82 p.P95L 3.35 72
p.R882H 19.00 48 p.R882H 1.46 82 p.P95H 0.86 73
p.R882H 1.18 49 p.R882C 2.62 82 p.P95H 0.84 77
p.R882S 1.74 49 p.R882C 6.15 89 p.P95L 0.97 79y
p.R882H 9.87 50 p.R882C 2.00 94 p.P95L 0.85 80yy
p.R882H 0.83 51 JAK2V617F p.V617F 1.56 34 p.P95H 6.67 80yy
p.R882C 1.10 51 p.V617F 4.91 42 p.P95L 0.96 81
p.R882C 12.50 52 p.V617F 7.72 45 p.P95H 6.40 82
p.R882C 1.28 53 p.V617F 0.85 62 p.P95L 2.74 85
p.R882C 2.47 54 p.V617F 25.44 64 p.P95R 7.52 87
p.R882H 1.95 55 p.V617F 7.41 65 p.P95L 5.84 88**
p.R882C 30.22 55 p.V617F 1.03 67 p.P95H 10.48 88**
p.R882C 1.22 56 p.V617F 0.88 71 p.P95R 2.71 88
p.R882H 0.91 58 p.V617F 3.75 71 p.P95R 17.05 90z
p.R882H 4.17 60 p.V617F 1.16 75 SF3B1 K700 p.K700E 1.04 76
p.R882H 5.90 60 p.V617F 2.30 77 p.K700E 6.63 81
p.R882H 9.60 60 p.V617F 1.92 78 p.K700E 0.79 82
p.R882H 2.73 60 p.V617F 2.26 80* p.K700E 12.59 83
p.R882C 9.33 60 p.V617F 4.25 80 p.K700E 8.77 83zz
p.R882H 7.03 61 p.V617F 1.92 80 p.K700E 1.02 84
p.R882C 1.21 61 p.V617F 3.71 80 p.K700E 0.85 90z
p.R882H 0.86 63 p.V617F 15.48 81 p.K700E 1.37 90
p.R882H 2.54 64 p.V617F 1.21 82 SF3B1 K666 p.K666N 1.33 70
p.R882H 3.19 67 p.V617F 1.62 85 p.K666N 5.01 79
p.R882H 2.74 70 p.V617F 0.83 85 p.K666N 13.36 79y
p.R882H 4.27 74 p.V617F 1.98 86 p.K666N 15.43 80*
p.R882H 0.85 74 p.V617F 25.94 88 p.K666N 4.60 81
p.R882H 0.85 75 p.V617F 10.88 88** p.K666E 1.09 83zz
p.R882C 1.12 77 p.V617F 2.94 90 p.K666N 35.11 86
p.R882C 1.15 78 p.V617F 1.23 90 p.K666N 19.70 86
p.R882H 1.26 79 KRAS G12 p.G12 R 0.94 55 p.K666N 16.55 86
p.R882H 16.66 80 p.G12S 2.78 78 p.K666E 3.34 95
p.R882C 4.28 80 NRAS G12 p.G12S 1.50 61
p.R882C 3.66 80 p.G12D 0.96 62
Mutations identified in the same sample are highlighted with the same symbol (*, **, y, yy, z, and zz).clones driven by spliceosomemutations. HSCs do not operate in
isolation; instead, their normal survival and behavior are closely
dependent on interactions with the hemopoietic microenviron-
ment (Calvi et al., 2003; Rossi et al., 2008; Zhang et al., 2003).
Therefore, both cell-intrinsic and microenvironmental factors in-
fluence hemopoietic aging (Rossi et al., 2008; Woolthuis et al.,
2011). For example, there is good evidence for age-related
changes in cell-intrinsic properties of HSCs in both mice (Cham-1242 Cell Reports 10, 1239–1245, March 3, 2015 ª2015 The Authorsbers et al., 2007; Rossi et al., 2005) and humans (Ru¨be et al.,
2011; Taraldsrud et al., 2009), and it is also clear that aging
has a profound effect on the hemopoietic niche, reducing its
ability to sustain polyclonal hemopoiesis, favoring oligo- or
monoclonality instead (Vas et al., 2012). These and many other
observations provide strong evidence that changes in the hemo-
poietic system subject HSCs to changing pressures during
normal aging, driving clonal selection (Rossi et al., 2008).
Figure 2. Proposed Kinetics of Hemopoietic Clones Driven by
Different Gene Mutations
Mutations such as DNMT3A R882H/C or JAK2 V617F drive a slow but inex-
orable clonal expansion, leading to the outgrowth of a detectable clone after a
certain latency. By contrast, mutations affecting spliceosome genes, such as
SF3B1 and SRSF2, and acquired at the same age for the purposes of this
model give no proliferative advantage initially but do so later in the context of
an aging hemopoietic compartment. Their effects may operate by prolonging
stem cell survival and repopulating fitness beyond that of normal stem cells or
by exploiting cell-extrinsic changes in the aging microenvironment.A striking example of such selection was described in a 115-
year-old woman whose peripheral white blood cells were shown
to be primarily the offspring of only two related HSC clones,
whose cargo of approximately 450 somatic mutations did not
include known leukemogenic mutations (Holstege et al., 2014).
In the absence of somatic driver mutations, it is probable that
such selection is driven by well-demonstrated epigenetic differ-
ences between individual HSCs (Fraga et al., 2005) or by sto-
chastic events. Furthermore, clonal hemopoiesis in the absence
of a known leukemia-driver mutation was also well documented
recently (Genovese et al., 2014), and whereas unknown or unde-
tected drivers may be responsible for many cases of this phe-
nomenon, it is also highly plausible that a stochastic process
of clonal selection or loss may operate in others. Our study pro-
vides evidence that spliceosome gene mutations offer a means
to exploit age-related changes in hemopoiesis to drive clonal he-
mopoiesis in advanced old age, an observation that blurs the
boundary between ‘‘driver’’ and ‘‘passenger’’ mutations. Such
a context dependency is not a surprising attribute for the effects
of spliceosomemutations, which have not, so far, been shown to
impart a primary proliferative advantage to normal hemopoietic
stem and progenitor cells (Matsunawa et al., 2014; Visconte
et al., 2012).
A final important finding of our study was the almost complete
absence of canonical NPM1 mutations in our collection of more
than 4,000 people, despite the use of a highly sensitive assay for
their detection, designed specifically for this study. Among more
than 10 million mapped reads covering this mutation hot spot,
we identified only four reads in a single sample reporting a ca-
nonical mutation (mutation A; TCTG duplication). Given their fre-
quency in myeloid leukemia (Cancer Genome Atlas Research
Network, 2013) and the fact that they are not late mutations
(Kro¨nke et al., 2013; Shlush et al., 2014), this observation frames
NPM1mutations as ‘‘gatekeepers’’ of leukemogenesis, i.e., theirCeacquisition appears to be closely associated with the develop-
ment of frank leukemia. In this light, the frequent co-occurrence
of DNMT3A and NPM1 mutations suggests that the former
behave as ‘‘rafts’’ that enable NPM1 mutant clones to be
founded and expanded, thus facilitating onward evolution to-
ward acute myeloid leukemia.
We used a highly sensitive method to search for evidence of
clonal hemopoiesis driven by 15 recurrent leukemogenic muta-
tions in more than 4,000 individuals. Our results demonstrate
that the incidence of clonal hemopoiesis is much higher than
suggested by exome-sequencing studies, that spliceosome
gene mutations drive clonal outgrowth primarily in the context
of an aging hemopoietic compartment, and that NPM1 muta-
tions do not drive ARCH, indicating that their acquisition is
closely associated with frank leukemia.
EXPERIMENTAL PROCEDURES
Patient Samples
Samples were obtained with written informed consent and in accordance with
the Declaration of Helsinki and appropriate ethics committee approvals from
all participants (approval reference numbers 10/H0604/02, 07/MRE05/44,
and 05/Q0106/74). Maternal consent was obtained for the use of cord blood
samples. Samples were obtained from 3,067 blood donors aged 17–70 years
(WTCCC; UK Blood Services 1 [UKBS1] and UKBS2 common controls),
1,152 unselected individuals aged 60–98 years (UKHLS; https://www.
understandingsociety.ac.uk/), 32 patients that had undergone a hemopoietic
stem cell transplant (12 autologous and 20 allogeneic; Tables S3 and S4)
1 month to 14 years previously, and 18 cord blood samples. Age distribution
of the WTCCC and UKHLS cohorts/samples is shown in Figure S1. Hemoglo-
bin concentrations were available for a total of 3,587 of the 4,067 samples from
which adequate sequencing data were obtained for analysis, including 102 of
105 samples with mutations. Full blood count results were available for 2,952
WTCCC samples. The average blood donation frequency for WTCCC donors
was 1.6 donations of one unit per year. Details of donations by individual par-
ticipants were not available.
Targeted Sequencing
Genomic DNA was used to simultaneously amplify several gene loci using
multiplex PCR, in order to capture and analyze 15 mutational hot spots en-
riched for, but not exclusive to, targets of mutations thought to arise early in
leukemogenesis (Table 1). We used three multiplex primer combinations
(Plex1-3), guided by our findings, to capture the targeted mutational hot spots
(Table S1). Primers were designed using the Hi-Plex PCR-MPS (massively
parallel sequencing) strategy (Nguyen-Dumont et al., 2013), except for JAK2
V617 and ‘‘Plex2’’ primers, which were designed using MPRIMER (Shen
et al., 2010). These and additional primer sequences used in each Plex and de-
tails of PCR- and DNA-sequencing protocols are detailed in Supplemental
Experimental Procedures. Methodological validation experiments are shown
in Figure S2.
Bioinformatic Analysis
Sequencing data were aligned to the human reference genome (hg19) using
BWA. Subsequently, the SAMTOOLS pileup command was used to generate
pileup files from the generated bam files (version 0.1.8; http://samtools.
sourceforge.net; Li et al., 2009). A flexible in-house Perl script generated by
our group, MIDAS (Conte et al., 2013), was modified in order to interrogate
only the hot spot nucleotide positions of interest (those with reported muta-
tions in the COSMIC database; Forbes et al., 2015) on the pileup file, consid-
ering only those reads with a sequence quality higher than 25 and a mapping
quality higher than 15. For each sample, the numbers of reads reporting the
reference and variant alleles at each position were extracted. VAFs were
derived by dividing the number of reads reporting the most-frequent variant
nucleotide to the total. In order to detect NPM1mutations with high sensitivity,ll Reports 10, 1239–1245, March 3, 2015 ª2015 The Authors 1243
we wrote a bespoke Perl script described in Supplemental Experimental
Procedures.
Statistical Analyses and Mutation-Calling Threshold
We chose a threshold VAF ofR0.008 (0.8%) to ‘‘call’’ clones with a heterozy-
gous mutation representing R1.6% of blood leukocytes. From validation ex-
periments and data analysis (see Supplemental Experimental Procedures
and Figure S2D), we determined that the maximum false-positive error rate
for calling a mutation (VAFR 0.008) due to variant allele counts that are solely
due to PCR-MiSeq error was negligible (p < 105). For comparisons of blood
cell counts and hemoglobin concentrations, we used non-paired t tests. For
summary statistics of read coverage (Table S2) and for the purposes of deriving
an estimate of the overall incidence of clonal hemopoiesis (Figure S4), we used
published tables of all mutations reported by three recent studies that em-
ployed whole-exome-sequencing analyses to identify individuals with clonal
hemopoiesis (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).
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